<?xml version="1.0" encoding="UTF-8"?>
<table id="PMC6963560/table_3" xmlns="http://www.w3.org/1999/xhtml">
 <caption>
  <label>Table 3</label>
  <p>Viral and clinical response after antiviral therapy with DAAs in patients with HCV-associated GN.</p>
 </caption>
 <thead>
  <tr>
   <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1" id="0-0-."> </th>
   <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1" id="0-1-.">DAAs</th>
   <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1" id="0-2-.">SVR12</th>
   <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1" id="0-3-.">Complete Clinical Response</th>
   <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1" id="0-4-.">Partial Clinical Response</th>
   <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1" id="0-5-.">Concomitant IS</th>
  </tr>
 </thead>
 <tbody>
  <tr>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Gragnani L, et al. (2016) ( 
    <i>n </i>= 4) 
   </td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SOF-based regimen</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4(100%)</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3(75%)</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1(25%)</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1(25%)</td>
  </tr>
  <tr>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sise M, et al. (2016) ( 
    <i>n </i>= 7) 
   </td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SOF+SIM ( 
    <i>n </i>= 6) 
    <br/>SOF+RBV ( 
    <i>n </i>= 1) 
   </td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6(86%)</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3(43%)</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4(57%)</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2(29%)</td>
  </tr>
  <tr>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Saadoun D, et al. (2016) ( 
    <i>n </i>= 5). 
   </td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SOF+RBV</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4(80%)</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4(80%)</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2(40%)</td>
  </tr>
  <tr>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sollima S, et al. (2016) ( 
    <i>n </i>= 5) 
   </td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SOF+RBV 
    <br/>SOF+DCV 
    <br/>SOF+SIM 
    <br/>3D 
   </td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5(100%)</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1(20%)</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td>
  </tr>
  <tr>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Emery J, et al. (2017) ( 
    <i>n </i>= 10) 
   </td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SOF+RBV 
    <br/>SOF+SIM 
    <br/>3D±RBV 
    <br/>SOF+LDV±RBV 
   </td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7(70%)</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2(20%)</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2(20%)</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4(40%)</td>
  </tr>
  <tr>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Saadoun D, et al. (2017) ( 
    <i>n </i>= 5) 
   </td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SOF+DCV</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5(100%)</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3(60%)</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1(20%)</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td>
  </tr>
  <tr>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bonacci M, et al. (2018) ( 
    <i>n </i>= 9) 
   </td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SOF-based regimen±RBV 
    <br/>3D±RBV 
    <br/>SIM+DCV 
    <br/>GZR+EBR 
    <br/>pegIFN+DAAs 
    <br/>FDV+DLR 
   </td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9(100%)</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6(67%)</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3(33%)</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5(55%)</td>
  </tr>
  <tr>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fabrizi F, et al. (2018) ( 
    <i>n </i>= 13) 
   </td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SOF+RBV ( 
    <i>n </i>= 6) 
    <br/>3D+RBV ( 
    <i>n </i>= 4) 
    <br/>SOF+LDV ( 
    <i>n </i>= 1) 
    <br/>SOF+DCV+RBV ( 
    <i>n </i>= 2) 
   </td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13(100%)</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3(23%)</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7(54%)</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9(69.2%)</td>
  </tr>
  <tr>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Obrisca B, et al. (2019) ( 
    <i>n </i>= 9) 
   </td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3D</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9(100%)</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2(23%)</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1(10%)</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6(67%)</td>
  </tr>
 </tbody>
 <tfoot>
  <p class="fn" charset="fn">
   <p>3D+ribavirin (RBV), ritonavir-boosted paritaprevir/ombitasvir/dasabuvir with or without RBV; EBR, elbasvir; FDV, faldaprevir; GRZ, grazoprevir; LDV, ledipasvir; PegIFN, pegylated interferon; SIM, simeprevir, SOF, sofosbuvir.</p>
  </p>
 </tfoot>
</table>
